Aminocarboxymuconate Semialdehyde Decarboxylase (ACMSD) Antibody (FITC)

Background

2-Amino-3-carboxymuconate-6-semialdehyde decarboxylase (ACMSD) is an enzyme involved in the tryptophan catabolic pathway, specifically in the kynurenine pathway. This pathway degrades tryptophan into several bioactive metabolites, some of which are precursors for NAD+ biosynthesis. ACMSD catalyzes the conversion of 2-amino-3-carboxymuconate-6-semialdehyde (ACMS) to 2-aminomuconate-6-semialdehyde (AMS), a step that diverts the pathway away from the production of quinolinic acid, a neuroactive compound. By regulating the flux of metabolites in the kynurenine pathway, ACMSD influences the balance between neurotoxic and neuroprotective metabolites. This enzyme is expressed in various tissues, including the brain, liver, and kidney, suggesting its importance in systemic metabolism and neuronal function. Dysregulation of ACMSD activity has been implicated in neurodegenerative diseases, such as Alzheimer's and Parkinson's disease, as well as psychiatric disorders like schizophrenia. Research into the molecular mechanisms and regulation of ACMSD holds promise for understanding the pathogenesis of these disorders and developing therapeutic interventions targeting the kynurenine pathway. Further investigation is needed to explore the potential of ACMSD modulation as a strategy for neuroprotection and the treatment of neurological and psychiatric conditions.